These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 22911011)

  • 1. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.
    Suthar AB; Lawn SD; del Amo J; Getahun H; Dye C; Sculier D; Sterling TR; Chaisson RE; Williams BG; Harries AD; Granich RM
    PLoS Med; 2012; 9(7):e1001270. PubMed ID: 22911011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa.
    Fatti G; Grimwood A; Nachega JB; Nelson JA; LaSorda K; van Zyl G; Grobbelaar N; Ayles H; Hayes R; Beyers N; Fidler S; Bock P
    Clin Infect Dis; 2020 Jan; 70(3):395-403. PubMed ID: 30877753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
    Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
    PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
    Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
    BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.
    Pepper DJ; Marais S; Wilkinson RJ; Bhaijee F; Maartens G; McIlleron H; De Azevedo V; Cox H; McDermid C; Sokhela S; Patel J; Meintjes G
    BMC Infect Dis; 2010 Mar; 10():83. PubMed ID: 20353569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis.
    Kufa T; Mabuto T; Muchiri E; Charalambous S; Rosillon D; Churchyard G; Harris RC
    PLoS One; 2014; 9(11):e111209. PubMed ID: 25393281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
    Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
    Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
    Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
    Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis.
    Burke RM; Rickman HM; Singh V; Corbett EL; Ayles H; Jahn A; Hosseinipour MC; Wilkinson RJ; MacPherson P
    J Int AIDS Soc; 2021 Jul; 24(7):e25772. PubMed ID: 34289243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.
    Hermans SM; Kiragga AN; Schaefer P; Kambugu A; Hoepelman AI; Manabe YC
    PLoS One; 2010 May; 5(5):e10527. PubMed ID: 20479873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
    Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
    Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.
    Suthar AB; Vitoria MA; Nagata JM; Anglaret X; Mbori-Ngacha D; Sued O; Kaplan JE; Doherty MC
    Lancet HIV; 2015 Apr; 2(4):e137-50. PubMed ID: 26424674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.